Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021379 | 1.00 | GRM5 (0.56) | GRM5CYP19A1CYP2A6F2HPGD | |
| SCHEMBL13642328 | 0.94 | GRM5 (0.52) | GRM5CYP19A1CYP2A6F2RAB9A | |
| SCHEMBL5021807 | 0.94 | GRM5 (0.52) | GRM5CYP19A1CYP2A6F2RAB9A | |
| SCHEMBL5022006 | 0.90 | GRM5 (0.63) | GRM5HPGDKDM4EALDH1A1GAA | |
| SCHEMBL5022007 | 0.90 | GRM5 (0.63) | GRM5HPGDKDM4EALDH1A1GAA | |
| SCHEMBL5021666 | 0.82 | GRM5 (0.60) | GRM5KDM4EALDH1A1GAANPC1 | |
| SCHEMBL5021667 | 0.82 | GRM5 (0.60) | GRM5KDM4EALDH1A1GAANPC1 | |
| SCHEMBL5021574 | 0.82 | GRM5 (0.55) | GRM5 | |
| SCHEMBL5021576 | 0.82 | GRM5 (0.55) | GRM5 | |
| SCHEMBL5021742 | 0.81 | GRM5 (0.54) | GRM5KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| WO-2012064603-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885CYP19A1 3967/4885CYP2A6 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.